Search - tctmd.com

Displaying 181 - 200 of 329

Sort: Relevancy | Date

Presentation TCT 2017

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus Antiplatelet Therapy

Presenter: Robert A. Harrington, Kurt Huber, Renato D. Lopes

November 01, 2017

Presentation TCT 2017

TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials

Presenter: Steven R. Bailey, Patrick W. Serruys, Angelo Biviano, MD

November 01, 2017

News Conference News TCT 2017

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Michael O'Riordan

October 31, 2017

Presentation TCT 2017

TCT 80: Incidence, Predictors, and Outcomes of New-Onset Atrial Fibrillation and Flutter After PCI or CABG for Left Main Disease: Analysis From the EXCEL Trial

Presenter: Davide Capodanno, Tullio Palmerini, Ioanna Kosmidou

October 31, 2017

Presentation TCT 2017

Case #2 Introduction: 85-Year-Old Patient With Previous Stents and Severe Aortic Stenosis, Reduced LVEF, Chronic Anemia, and Mild Renal Impairment Develops Atrial Fibrillation After TAVR

Presenter: Nick Curzen, Rod H. Stables

October 31, 2017

Presentation TCT 2017

Debate: LAA Closure Should Be Considered in Most Patients With Nonvalvular Atrial Fibrillation!

Presenter: Christopher B. Granger, Horst Sievert, Maurice Buchbinder

October 30, 2017

Presentation TCT 2017

Atrial Fibrillation and PCI/ACS: NOACs, Dual Therapy, and Triple Therapy

Presenter: Thomas H. Maloney, C. Michael Gibson

October 30, 2017

Presentation TCT 2017

Catheter Ablation and/or LAA Closure for Atrial Fibrillation: Competitive or Complementary?

Presenter: Christopher B. Granger, Horst Sievert, Vivek Y. Reddy

October 30, 2017

Presentation TCT 2017

Current Guidelines and Recommendations for LAA Closure in Nonvalvular Atrial Fibrillation

Presenter: Christopher B. Granger, Horst Sievert, Pascal Vranckx

October 30, 2017

Presentation TCT 2017

Origin of Thromboemboli in Atrial Fibrillation: Valvular vs Non-Valvular AF, Large vs Small Left Atria, and Other Considerations

Presenter: Christopher B. Granger, Horst Sievert, Renu Virmani

October 30, 2017

News Conference News TCT 2017

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

Michael O'Riordan

October 30, 2017

Presentation TCT 2016

AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

Presenter: Martin B. Leon, Louis A. Cannon, David Hildick-Smith

November 02, 2016

Presentation TCT 2016

WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

Presenter: Martin B. Leon, Louis A. Cannon, David R. Holmes Jr.

November 02, 2016

Presentation TCT 2016

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Vivek Y. Reddy

November 01, 2016

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

Presentation TCT 2016

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Presenter: Martin W. Bergmann, Samir R. Kapadia, Jason H. Rogers

November 01, 2016

Presentation TCT 2016

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Presenter: Martin W. Bergmann, Samir R. Kapadia, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Presenter: Martin W. Bergmann, Samir R. Kapadia, Ashish Pershad

November 01, 2016

Presentation TCT 2016

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Roxana Mehran

November 01, 2016

Advertisement

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus Antiplatelet Therapy

TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

TCT 80: Incidence, Predictors, and Outcomes of New-Onset Atrial Fibrillation and Flutter After PCI or CABG for Left Main Disease: Analysis From the EXCEL Trial

Case #2 Introduction: 85-Year-Old Patient With Previous Stents and Severe Aortic Stenosis, Reduced LVEF, Chronic Anemia, and Mild Renal Impairment Develops Atrial Fibrillation After TAVR

Debate: LAA Closure Should Be Considered in Most Patients With Nonvalvular Atrial Fibrillation!

Atrial Fibrillation and PCI/ACS: NOACs, Dual Therapy, and Triple Therapy

Catheter Ablation and/or LAA Closure for Atrial Fibrillation: Competitive or Complementary?

Current Guidelines and Recommendations for LAA Closure in Nonvalvular Atrial Fibrillation

Origin of Thromboemboli in Atrial Fibrillation: Valvular vs Non-Valvular AF, Large vs Small Left Atria, and Other Considerations

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content